Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies
Donald Trump had significant trades made on his behalf in Eli Lilly shares, benefiting from policies during his administration. Financial disclosures revealed trades worth between $220 million and $750 million in the first quarter of 2026. The Trump Organization stated that Trump does not directly manage these investments, which are handled by third-party financial institutions.
- ▪Eli Lilly shares worth up to $680,000 were acquired on Trump's behalf between January and March 2026.
- ▪The trades coincided with government actions that benefited Eli Lilly's weight-loss drugs.
- ▪Trump's investment holdings are managed by third-party financial institutions, according to the Trump Organization.
Opening excerpt (first ~120 words) tap to expand
The logo for Eli Lilly And Co hangs at the entrance to the New York Stock Exchange after the opening bell on Wall Street on 11 May 2026 in New York City. Photograph: John Angelillo/UPI/ShutterstockView image in fullscreenThe logo for Eli Lilly And Co hangs at the entrance to the New York Stock Exchange after the opening bell on Wall Street on 11 May 2026 in New York City. Photograph: John Angelillo/UPI/ShutterstockDonald TrumpTrades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policiesFilings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companiesAnna BettsTue 19 May 2026 12.38 EDTLast modified on Tue 19 May 2026 12.39 EDTSharePrefer the Guardian on GoogleHundreds of…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — US.
Discussion
0 commentsMore from The Guardian — US
